[1] |
中华医学会儿科学分会肾脏学组.儿童激素敏感、复发/依赖肾病综合征诊治循证指南(2016)[J].中华儿科杂志,2017,55(10):729-734.DOI:10.3760/cma.j.issn.0578-1310.2017.10.003.The Subspecialty Group of Renal Diseases,the Society of Pediatrics,Chinese Medical Association.Evidence-based guideline on diagnosis and treatment of steroid-sensitive,relapsing/steroid-dependent nephrotic syndrome in children(2016) [J].Chin J Pediatr,2017,55(10):729-734.DOI:10.3760/cma.j.issn.0578-1310.2017.10.003.
|
[2] |
郭艺桢,袁芳,陈育才.1型神经纤维瘤病发病机制的研究进展[J].国际儿科学杂志,2024,51(1):23-28.DOI:10.3760/cma.j.issn.1673-4408.2024.01.005.Guo YZ,Yuan F,Chen YC.Progress on the pathogenesis of neurofibromatosis type 1[J].Int J Pediatr,2024,51(1):23-28.DOI:10.3760/cma.j.issn.1673-4408.2024.01.005.
|
[3] |
智元昭,曹璐,窦文杰,等.利妥昔单抗治疗儿童非复杂性激素依赖型肾病综合征疗效分析[J/OL].中华妇幼临床医学杂志(电子版),2023,19(1):54-60.DOI:10.3877/cma.j.issn.1673-5250.2023.01.008.Zhi YZ,Cao L,Dou WJ,et al.Efficacy of rituximab in the treatment of uncomplicated steriod-dependent nephrotic syndrome in children [J/OL].Chin J Obstet Gynecol Pediatr(Electron Ed),2023,19(1):54-60.DOI:10.3877/cma.j.issn.1673-5250.2023.01.008.
|
[4] |
Tarrass F.Focal and segmental glomerulosclerosis and von Recklinghausen's neurofibromatosis:coincidental or associated?[J].Saudi J Kidney Dis Transpl,2008,19(3):453-454.
|
[5] |
Cheng B,Yang H,Huang L,et al.Nephrotic syndrome in a child with neurofibromatosis type 1:a case report and literature review[J].Nephrology (Carlton),2024,29(12):973-976.DOI:10.1111/nep.14393.
|
[6] |
Rhee H,Kim S,Lee W,et al.Immunoglobulin A nephropathy in a patient with neurofibromatosis type 1:a case report and literature review[J].Medicine (Baltimore),2021,100(42):e27572.DOI:10.1097/MD.0000000 000027572.
|
[7] |
Lin F,Zhang D,Chang J,et al.THSD7A-associated membranous nephropathy in a patient with neurofibromatosis type 1[J].Eur J Med Genet,2018,61(2):84-88.DOI:10.1016/j.ejmg.2017.10.014.
|
[8] |
Orera A,Lacarra S,Fernández L,et al.Secondary glomerulonephritis in neurofibromatosis type 1.Two case reports[J].An Sist Sanit Navar,2019,42(3):345-349.Spanish.DOI:10.23938/ASSN.0720.
|
[9] |
Varyani UT,Shah NM,Shah PR,et al.C1q nephropathy in a patient of neurofibromatosis type 1:a rare case report[J].Indian J Nephrol,2019,29(2):125-127.DOI:10.4103/ijn.IJN_353_17.
|
[10] |
Van-Gils J,Harambat J,Jubert C,et al.Atypical hematologic and renal manifestations in neurofibromatosis typeⅠ:coincidence or pathophysiological link? [J].Eur J Med Genet,2014,57(11-12):639-642.DOI:10.1016/j.ejmg.2014.09.001.
|
[11] |
Hyun JI,Min JW,Lee HM,et al.Minimal change nephrotic syndrome showing complete remission after resection of a neurofibroma in a typeⅠneurofibromatosis patient[J].Korean J Intern Med,2017,32(1):186-189.DOI:10.3904/kjim.2015.016.
|
[12] |
Chang KY,Kim HW,Kim YS.Case of immunoglobulin M nephropathy in a patient with neurofibromatosis type 1[J].Nephrology (Carlton),2015,20(9):666-667.DOI:10.1111/nep.12487.
|
[13] |
Gersch MS,Talor Z.Focal segmental glomerular sclerosis in a patient with neurofibromatosis typeⅠ[J].Am J Kidney Dis,2006,47(1):e17-e19.DOI:10.1053/j.ajkd.2005.09.017.
|
[14] |
Wani MM,Reshi AR,Banday KA,et al.von Recklinghausen's neurofibromatosis associated with membranous glomerulonephritis[J].Saudi Med J,2006,27(4):534-535.
|
[15] |
Afshinnia F,Vega-Warner V,Killen P.Focal segmental glomerulosclerosis in association with neurofibromatosis type 1:a case report and proposed molecular pathways[J].Clin Kidney J,2013,6(2):208-210.DOI:10.1093/ckj/sft010.
|
[16] |
林芙君,张丹,常娟,等.1型神经纤维瘤病患者的THSD7A相关膜性肾病1例 [J].中国临床案例成果数据库,2022,4(1):E06390-E06390.DOI:10.3760/cma.j.cmcr.2022.e06390.Lin FJ,Zhang D,Chang J,et al.A case of membranous nephropathy associated with THSD7A in a patient with neurofibromatosis type 1[J].Chin J Clin Case Res Database,2022,4(1):E06390-E06390.DOI:10.3760/cma.j.cmcr.2022.e06390.
|
[17] |
刘竹枫,王文红,郭珍,等.两例散发1型神经纤维瘤病合并肾病综合征患儿的遗传学分析[J].中华医学遗传学杂志,2022,39(12):1349-1353.DOI:10.3760/cma.j.cn511374-20210916-00755.Liu ZF,Wang WH,Guo Z,et al.Genetic analysis of two sporadic cases of neurofibromatosis type 1 in children with nephrotic syndrome[J].Chin J Med Genet,2022,39(12):1349-1353.DOI:10.3760/cma.j.cn511374-20210916-00755.
|
[18] |
张超,滕利.神经纤维瘤病的相关因素与治疗进展[J].中国美容医学杂志,2010,19(1):133-136.DOI:10.3969/j.issn.1008-6455.2010.01.062.Zhang C,Teng L.Research progress on related factors and treatment of neurofibromatosis[J].Chin J Beaut Med,2010,19(1):133-136.DOI:10.3969/j.issn.1008-6455.2010.01.062.
|
[19] |
Srinivasan A,Krishnamurthy G,Fontalvo-Herazo L,et al.Spectrum of renal findings in pediatric fibromuscular dysplasia and neurofibromatosis type 1[J].Pediatr Radiol,2011,41(3):308-316.DOI:10.1007/s00247-010-1854-9.
|
[20] |
Kokubo T,Hiki Y,Horii A,et al.Recklinghausen's neurofibromatosis associated with membranous nephropathy[J].Nephron,1993,65(3):486.DOI:10.1159/000 187543.
|
[21] |
Bollag G,McCormick F.Ras regulation.NF is enough of GAP[J].Nature,1992,356(6371):663-664.DOI:10.1038/356663a0.
|
[22] |
Shaw RJ,Cantley LC.Ras,PI(3)K and m TOR signalling controls tumour cell growth[J].Nature,2006,441(7092):424-430.DOI:10.1038/nature04869.
|
[23] |
Fehrenbacher N,Bar-Sagi D,Philips M.Ras/MAPK signaling from endomembranes[J].Mol Oncol,2009,3(4):297-307.DOI:10.1016/j.molonc.2009.06.004.
|
[24] |
Huynh C,Ryu J,Lee J,et al.Nutrient-sensing m TORC1 and AMPK pathways in chronic kidney diseases[J].Nat Rev Nephrol,2023,19(2):102-122.DOI:10.1038/s41581-022-00648-y.
|
[25] |
Adella A,de Baaij J.m TOR signaling in renal ion transport[J].Acta Physiol( Oxf),2023,238(1):e13960.DOI:10.1111/apha.13960.
|
[26] |
Ito N,Nishibori Y,Ito Y,et al.m TORC1 activation triggers the unfolded protein response in podocytes and leads to nephrotic syndrome[J].Lab Invest,2011,91(11):1584-1595.DOI:10.1038/labinvest.2011.135.
|
[27] |
Gödel M,Hartleben B,Herbach N,et al.Role of m TOR in podocyte function and diabetic nephropathy in humans and mice[J].J Clin Invest,2011,121(6):2197-2209.DOI:10.1172/JCI44774.
|
[28] |
Koshikawa M,Mukoyama M,Mori K,et al.Role of p38 mitogen-activated protein kinase activation in podocyte injury and proteinuria in experimental nephrotic syndrome[J].J Am Soc Nephrol,2005,16(9):2690-2701.DOI:10.1681/ASN.2004121084.
|
[29] |
Sakai N,Wada T,Furuichi K,et al.p38 MAPK phosphorylation and NF-kappa B activation in human crescentic glomerulonephritis[J].Nephrol Dial Transplant,2002,17(6):998-1004.DOI:10.1093/ndt/17.6.998.
|
[30] |
Whaley-Connell A,Habibi J,Panfili Z,et al.AngiotensinⅡactivation of m TOR results in tubulointerstitial fibrosis through loss of N-cadherin[J].Am J Nephrol,2011,34(2):115-125.DOI:10.1159/000329327.
|